Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Liabilities and Shareholders Equity: 2017-2025

Historic Liabilities and Shareholders Equity for Autolus Therapeutics (AUTL) over the last 6 years, with Sep 2025 value amounting to $661.9 million.

  • Autolus Therapeutics' Liabilities and Shareholders Equity fell 20.01% to $661.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year decrease of 1.55%. This contributed to the annual value of $782.7 million for FY2024, which is 108.51% up from last year.
  • Autolus Therapeutics' Liabilities and Shareholders Equity amounted to $661.9 million in Q3 2025, which was down 8.19% from $721.0 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Liabilities and Shareholders Equity registered a high of $901.4 million during Q1 2024, and its lowest value of $263.8 million during Q3 2022.
  • Its 3-year average for Liabilities and Shareholders Equity is $653.4 million, with a median of $721.0 million in 2025.
  • As far as peak fluctuations go, Autolus Therapeutics' Liabilities and Shareholders Equity fell by 23.43% in 2023, and later soared by 108.51% in 2024.
  • Over the past 5 years, Autolus Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $405.6 million in 2021, then grew by 20.89% to $490.3 million in 2022, then decreased by 23.43% to $375.4 million in 2023, then spiked by 108.51% to $782.7 million in 2024, then decreased by 20.01% to $661.9 million in 2025.
  • Its last three reported values are $661.9 million in Q3 2025, $721.0 million for Q2 2025, and $746.3 million during Q1 2025.